Strategies for human leukocyte antigen antibody detection

Current Opinion in Organ Transplantation

Volumn 14, Issue 4, 2009, Pages 392-397

  Bray, Robert A ^a   Gebel, Howard M ^a  

^a EMORY UNIVERSITY HOSPITAL   (United States)

Author keywords

Antibody mediated rejection; HLA antibody; Transplantation; Virtual crossmatch

Indexed keywords

HLA ANTIBODY;

AFRICAN AMERICAN; ANTIBODY DETECTION; CYTOMETRY; HUMAN; REVIEW; SURVIVAL; TRANSPLANTATION;

ANTIBODIES; GRAFT REJECTION; HISTOCOMPATIBILITY; HISTOCOMPATIBILITY TESTING; HLA ANTIGENS; HUMANS; OBSERVER VARIATION; ORGAN TRANSPLANTATION; QUALITY CONTROL; REAGENT KITS, DIAGNOSTIC; REPRODUCIBILITY OF RESULTS; TISSUE DONORS;

EID: 68849087407     PISSN: 10872418     EISSN: 15317013     Source Type: Journal    
DOI: 10.1097/MOT.0b013e32832d31c7     Document Type: Review

References (34)

1. Patel R, Terasaki PI. Significance of the positive crossmatch test in kidney transplantation. N Engl J Med 1969; 280:735-739.
2. Gebel HM, Bray RA, Nickerson PW. Pretransplant assessment of donorreactive, HLA-specific antibodies in renal transplantation: contraindication vs. risk. Am J Transplant 2003; 3:1488-1500.
3. Amos DB, Bashir H, Bogle W, et al. A simple microtoxicity test. Transplantation 1970; 7:220-223.
4. Johnson AH, Rossen RD, Butler WT. Detection of alloantibodies using a sensitive antiglobulin microcytotoxicity test: identification of low levels of preformed antibodies in accelerated allograft rejection. Tissue Antigens 1972; 2:215-226.
5. Cross DE, Whittier FC, Weaver P, Foxworth J. A comparison of the antiglobulin versus extended incubation time crossmatch results in 223 renal transplants. Transplant Proc 1977; 9:1803-1806. (Pubitemid 8256668)
6. Fuller TC, Cosimi AB, Russell PS. Use of an antiglobulin-ATG reagent for detection low levels of alloantibody-improvement of allograft survival in presensitized recipients. Transplant Proc 1978; 10:463-486.
7. Garovoy MR, Rheinschmilt MA, Bigos M, et al. Flow cytometry analysis: a high technology crossmatch technique facilitating transplantation. Transplant Proc 1983; 15:1939-1944. (Pubitemid 14233896)
8. Braun WE. Laboratory and clinical management of the highly sensitized organ transplant recipient. Hum Immunol 1989; 26:245-260. (Pubitemid 20001194)
9. Gebel HM, Bray RA. Laboratory assessment of HLA antibodies circa 2006: making sense of sensitivity. Transplant Rev 2006; 20:189-194.
10. Bray RA, Nickerson PW, Kerman RH, Gebel HM. Evolution of HLA antibody detection: technology emulating biology. Immunol Res 2004; 29:41-53.
11. Kao KJ, Scornik JC, Small SJ. Enzyme-linked immunoassay for anti-HLA antibodies: an alternative to panel studies by lymphocytotoxicity. Transplantation 1993; 55:192-196.
12. Pei R, Wang G, Tarsitani C, Rojo et al. Simultaneous HLA Class I and Class II antibodies screening with flow cytometry. Hum Immunol 1998; 5:313-322. (Pubitemid 28225990)
13. Kerman RH, Susskind B, Buyse I, et al. Flow cytometry-detected IgG is not a contraindication to renal transplantation: IgM may be beneficial to outcome. Transplantation 1999; 68:1855. (Pubitemid 30027337)
14. van den Berg-Loonen M, Billen EVA, Voorter CEM, et al. Clinical relevance of pretransplant donor-directed antibodies detected by single antigen beads in highly sensitized renal transplant patients. Transplantation 2008; 85:1086-1090. Paper discusses the correlation between HLA antibody concentration as assessed by single-antigen beads and clinical outcomes.
15. Haas M, Rahman MH, Racusen LC, et al. C4d and C3d staining in biopsies of ABO- and HLA-incompatible renal allografts: correlation with histologic findings. AJT 2006; 6:1829-1840. (Pubitemid 44024954)
16. Jordan SC, Vo AA, Peng A, et al. Intravenous gammaglobulin (IVIG): a novel approach to improve transplant rates and outcomes in highly HLA-sensitized patients. Am J Transplant 2006; 6:459. (Pubitemid 43382131)
17. Rees M, Kopke J, Pelletier R, et al. A nonsimultaneous, extended, altruisticdonor chain. N Engl, J Med 2009; 360:1096-1101.
18. Patel AM, Pancoska C, Mulgaonkar S, Weng FL. Renal transplantation in patients with pretransplant donor-specific antibodies and negative flow cytometry crossmatches. Am J Transplant 2007; 7:2371-2377. (Pubitemid 47347867)
19. Lin A, Xu H, Yan W. Modulation of HLA expression in human cytomegalovirus immune evasion. Cell & Mol Immunol 2007; 4:91-98.
20. Kuipers K, Biesta P, Groothuis T, et al. Statins affect cell-surface expression of major histocompatibility complex II molecules by disrupting cholesterolcontaining microdomains. Hu Immunol 2005; 66:653-665. (Pubitemid 40922554)
21. Deng C-T, El-Awar N, Ozawa M, et al. Human leukocyte antigen class II DQ alpha and beta epitopes identified from sera of kidney allograft recipients. Transplantation 2008; 86:452-459. This paper clearly shows that patients make antibodies against both DQB and DQA epitopes.
22. Bray RA, Gebel HM. Allele specific HLA alloantibodies. Implication for organ allocation. Am J Transplant 2005; 5 (s11):488.
23. Bartel G, Wahrmann M, Exner M, et al. Determinants of the complement-fixing ability of recipient presensitization against HLA antigens. Transplantation 2007; 83:727-733. (Pubitemid 46569190)
24. Bartel G, Wahrmann M, Exner M, et al. In vitro detection of C4d-fixing HLA antibodies: associations with capillary C4d deposition in kidney grafts. Am J Transplant 2008; 8:41-49. This paper demonstrates the clinical utility of measuring complement activation via C4d deposition, in renal transplantation.
25. Smith J, Hamour I, Banner N, Rose M. C4d fixing, Luminex binding antibodies: a new tool for prediction of graft failure after heart transplantation. Am J Transplant 2007; 7:2809-2815. (Pubitemid 350045767)
26. Böhmig GA, Bartel G, Wahrmann M. Antibodies, isotypes and complement in allograft rejection. Curr Opin Organ Transplant 2008; 13:411-418. Paper demonstrates the association of IgG isotypes and allograft rejection.
27. Saw CL, Bray RA, Gebel HM. Cytotoxicity and antibody binding by flow cytometry: a single assay to simultaneously assess two parameters. Cytometry B Clin Cytom 2008; 74:287-294. This paper presents a novel technique to simultaneously assess antibody binding and complement activation on cellular targets.
28. Vo A, Lukovsky M, Toyoda M, et al. Rituximab and intravenous immune globulin for desensitization during renal transplantation. N E J M 2008; 359:242-251. (Pubitemid 352008439)
29. Gloor J, Cosio F, Lager J, Stegall MD. The spectrum of antibody-mediated renal allograft injury: implications for treatment. Am J Transplant 2008; 8:1367-1373. (Pubitemid 351989489)
30. Thielke J, West-Thielke P, Herren H, et al. Living donor kidney transplantation across positive crossmatch: The University of Illinois at Chicago experience. Transplantation 2008; 87:268-273. Paper shows increased antibody-mediated rejection rates following desensitization and living donor transplantation.
31. Haririan A, Nogueira J, Kukuruga D, et al. Positive cross-match living donor kidney transplantation: longer-term outcomes. Am J Transplant 2009; 9:536-542. Paper discusses decreased long-term survival in patients receiving living donor transplants following desensitization for a positive crossmatch.
32. West-Thielke P, Herren H, Thielke J, et al. Results of positive cross-match transplantation in African American renal transplant recipients. Am J Transplant 2008; 8:348-354. Paper shows decreased graft survival among African-American recipients compared to non-African-American recipients following desensitization and renal transplantation.
33. Perry DK, Burns JM, Pollinger HS, et al. Proteasome inhibition causes apoptosis of normal human plasma cells preventing alloantibody production. Am J Transplantation 2009; 9:209-210. Paper illustrates the potential for bortezomib to inhibit plasma cell function in renal transplant patients.
34. Everly MJ, Everly JJ, Susskind B, et al. Bortezomib provides effective therapy for antibody and cell-mediated acute rejection. Transplantation 2008; 86:1754-1761. Paper illustrates the clinical utility of bortezomib in reducing HLA antibody titer and reversing antibody mediated rejection.